Skip to main content
. 2013 Aug 30;305(9):L625–L634. doi: 10.1152/ajplung.00068.2013

Fig. 5.

Fig. 5.

TMEM16A-specific blockade via functional antibody treatment corroborates pharmacological TMEM16A antagonist effects on STICs. A and B: representative whole cell recordings of STICs in immortalized human airway smooth muscle cells following incubation with vehicle (A) or TMEM16A antibody (B). C and D: antibody-mediated blockade of TMEM16A led to a functional loss of STIC amplitude and frequency compared with vehicle-treated cells (*P < 0.05, and *P < 0.05, respectively).